Guidance for palivizumab prophylaxis and implications for compliance
Sign Up to like & getrecommendations! Published in 2021 at "Pediatric Pulmonology"
DOI: 10.1002/ppul.25634
Abstract: Palivizumab is a synthetic monoclonal antibody targeting the F‐protein spike of the respiratory syncytial virus. First approved by the US Food and Drug Administration (FDA) in 1998, its indicated usage mirrored the American Academy of… read more here.
Keywords: policy; compliance; study; prophylaxis ... See more keywords
Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Pediatrics"
DOI: 10.1007/s00431-021-04216-7
Abstract: Respiratory syncytial virus (RSV) is a common pathogen that causes extremely severe respiratory symptoms in the first few weeks and months of life. In infants with cardiopulmonary diseases, RSV infections have a significant clinical impact.… read more here.
Keywords: respiratory syncytial; syncytial virus; hospitalisation; risk factors ... See more keywords
Cost Savings Without Increased Risk of Respiratory Hospitalization for Preterm Children After the 2014 Palivizumab Policy Update.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of perinatology"
DOI: 10.1055/a-1845-2184
Abstract: OBJECTIVE To compare rates of hospitalizations for respiratory illnesses in preterm and full-term children for four years before and after the 2014 update to the American Academy of Pediatrics (AAP) respiratory syncytial (RSV) immunoprophylaxis guidance,… read more here.
Keywords: rsv; palivizumab; policy; hospitalization ... See more keywords
Palivizumab’s real-world effectiveness: a population-based study in Ontario, Canada, 1993–2017
Sign Up to like & getrecommendations! Published in 2020 at "Archives of Disease in Childhood"
DOI: 10.1136/archdischild-2020-319472
Abstract: Objective To evaluate the effectiveness of two palivizumab programmes targeting high-risk infants, defined by prematurity, diagnosis of comorbidities and geography, and assess potential disparities by neighbourhood income. Design Controlled, interrupted time series. Setting Ontario, Canada.… read more here.
Keywords: rsv; ontario canada; palivizumab; rsv related ... See more keywords
P81 What is the ideal target preterm population that might benefit from the expensive palivizumab prophylaxis?
Sign Up to like & getrecommendations! Published in 2017 at "Thorax"
DOI: 10.1136/thoraxjnl-2017-210983.223
Abstract: Introduction Palivizumab is a monoclonal antibody that reduces the likelihood of serious respiratory tract infection by Respiratory Syncytial Virus (RSV) in infants with Chronic Lung Disease (CLD) defined as an ongoing oxygen requirement at 36… read more here.
Keywords: aap criteria; additional babies; palivizumab; jcvi criteria ... See more keywords
Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six‐Year Follow‐up Study
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Respiratory and Critical Care Medicine"
DOI: 10.1164/rccm.201609-1812oc
Abstract: Rationale: Respiratory syncytial virus (RSV) induces not only infantile recurrent wheezing but also potentially atopic asthma. Objectives: To test the effect of RSV infection on development of subsequent atopic asthma, we evaluated whether palivizumab, an… read more here.
Keywords: recurrent wheezing; atopic asthma; study; preterm infants ... See more keywords
Palivizumab and Long-term Outcomes in Cystic Fibrosis
Sign Up to like & getrecommendations! Published in 2019 at "Pediatrics"
DOI: 10.1542/peds.2018-3495
Abstract: In this study, we explore palivizumab’s potential benefits related to longer-term outcomes (lung function at age 7, first acquisition of Pseudomonas, and hospitalizations) in children with CF. BACKGROUND: The American Academy of Pediatrics does not… read more here.
Keywords: longer term; cystic fibrosis; term outcomes; palivizumab ... See more keywords
Partial Degradation of Recombinant Antibody Functional Activity During Infant Gastrointestinal Digestion: Implications for Oral Antibody Supplementation
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Nutrition"
DOI: 10.3389/fnut.2020.00130
Abstract: Oral administration of engineered immunoglobulins has the potential to prevent enteric pathogen-induced diarrhea in infants. To prevent infection, these antibodies need to survive functionally intact in the proteolytic environment of the gastrointestinal tract. This research… read more here.
Keywords: recombinant antibody; vivo digestion; antibody; digestion ... See more keywords